U.S. markets closed
  • S&P Futures

    3,834.00
    +6.00 (+0.16%)
     
  • Dow Futures

    31,396.00
    +25.00 (+0.08%)
     
  • Nasdaq Futures

    12,804.75
    -27.00 (-0.21%)
     
  • Russell 2000 Futures

    2,191.90
    -8.10 (-0.37%)
     
  • Crude Oil

    63.13
    -0.40 (-0.63%)
     
  • Gold

    1,772.40
    -3.00 (-0.17%)
     
  • Silver

    27.39
    -0.30 (-1.08%)
     
  • EUR/USD

    1.2170
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.4001
    -0.0012 (-0.09%)
     
  • USD/JPY

    106.0000
    -0.2300 (-0.22%)
     
  • BTC-USD

    47,406.64
    -3,177.82 (-6.28%)
     
  • CMC Crypto 200

    944.15
    -50.51 (-5.08%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,446.17
    -722.10 (-2.39%)
     

Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Virtual Healthcare Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Wednesday, June 3rd, 2020 at 8:30 a.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors & Media" section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which Kala recently resubmitted its New Drug Application to the FDA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005003/en/

Contacts

Investor Contact:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200